The Latest Cardiac and Vascular News
Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis Fourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year period Fourth quarter 2020 adjusted diluted EPS from continuing […]
Q4 2020 reported revenue of $258.0 million, approximately equal to Q4 2019 revenue Q4 2020 core revenue on a constant currency basis* down (1.0)% compared to Q4 2019 Q4 2020 GAAP EPS of $0.27, compared to GAAP loss per share of ($0.08) in Q4 2019 Q4 2020 non-GAAP EPS* of […]
ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said […]
VANCOUVER and MINNEAPOLIS, Feb. 24, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), has received written notification (the “Nasdaq Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for […]
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA® in Europe and Continue to Advance Commercial Launch Plans for Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. […]
Successfully launched CAPLYTA® (lumateperone) in late March 2020 and demonstrated strong commercial execution in the midst of COVID-19. CAPLYTA achieved net product revenues of $12.4 million and $22.5 million for fourth quarter and full year 2020, respectively. Fourth quarter CAPLYTA total prescriptions (TRx) increased 77% versus the previous quarter. Pursuing CAPLYTA […]
Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) LAS VEGAS, Feb. 25, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is […]
BGF announces multi-million investment in Vasorum – high-growth medical device business based in Dublin Ireland DUBLIN, IRELAND, February 25, 2021 /EINPresswire.com/ — BGF announces multi-million investment in Vasorum – high-growth Medical device business based in Dublin 7th Irish investment by BGF in 2 years Thursday 25th February 2021 BGF – […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020. For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6 million, a decrease of 6.3 percent on a reported basis and a decline […]
– Transaction furthers Terumo’s efforts to improve patient outcomes and decrease healthcare costs through personalized predictive analytics and clinical decision support at the point of care – TOKYO, Feb. 23, 2021 /PRNewswire/ — Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all […]
